07:00 , Aug 22, 2011 |  BC Week In Review  |  Company News

BAC B.V., Bristol-Myers deal

BAC will generate CaptureSelect custom affinity ligands for purification and analysis of Bristol-Myers’ Adnectin compounds. Adnectins are proteins derived from fibronectin, an extracellular protein in human serum. Bristol-Myers gained rights to the compounds through its...
07:00 , Jul 27, 2009 |  BioCentury  |  Strategy

Longer-term thinking

Having spent the last two years taking care of its upcoming patent cliff, Bristol-Myers Squibb Co. is now focused on stage three of its growth plan, beefing up its post-2014 pipeline and biologics platform with...
08:00 , Dec 15, 2008 |  BioCentury  |  Strategy

BMS cancer pipeline

BMS cancer pipeline Compound [partner] Target Lead indication Status Erbitux cetuximab [Merck KGaA (Xetra:MRK)/Eli Lilly (NYSE:LLY)] Epidermal growth factor (EGF) receptor 1 (HER1) (ErbB1) Colorectal cancer; squamous cell carcinoma...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Company News

Adnexus, Bristol-Myers deal

BMY will acquire Adnexus for $430 million in cash, plus up to $75 million in milestones. BMY said the acquisition will advance its biologics strategy across multiple therapeutic areas. Adnexus' lead compound is Angiocept...
07:00 , Oct 1, 2007 |  BioCentury  |  Strategy

Straw into gold

The acquisition of Adnexus Therapeutics Inc. by Bristol-Myers Squibb Co. is an object lesson in how one company can fail to make the proper use of a foundation technology while another acquires it and in...
00:24 , Sep 25, 2007 |  BC Extra  |  Top Story

Bristol-Myers acquiring Adnexus

BMY will acquire Adnexus (Waltham, Mass.) for $430 million in cash. Adnexus is also eligible for $75 million in milestones. Adnexus' lead compound is Angiocept ( CT-322), a VEGF receptor 2 antagonist in Phase I...
07:00 , Sep 3, 2007 |  BioCentury  |  Strategy

Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing power...
07:00 , Aug 27, 2007 |  BC Week In Review  |  Clinical News

Adnexus preclinical data

In animals, CT-322 inhibited tumor growth and reduced metastases compared with controls. The protein therapeutic that inhibits vascular endothelial growth factor (VEGF) receptor 2 ( KDR/Flk-1) also decreased the density of tumor microvessels and...
07:00 , Aug 27, 2007 |  BioCentury  |  Finance

Ebb & Flow

Activist investors enjoyed an immediate pop after PDL BioPharma CEO Mark McDade announced last week that he would resign by year end. The news boosted the shares $2.65 (13%) to $23.81 on the week, while...
23:04 , Aug 22, 2007 |  BC Extra  |  Financial News

Adnexus files for IPO

Adnexus (Waltham, Mass.) filed to raise up to $86.3 million in an IPO underwritten by Lehman; UBS; Cowen; and Lazard. Adnexus plans to begin Phase II testing of Angiocept ( CT-322), a VEGF receptor 2...